Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver
Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
To study the effectiveness and safety of adding Rosiglitazone, an insulin sensitizing agent
to people with chronic hepatitis C infection genotype 1 with fatty liver disease, who are
being treated with standard therapy. Standard therapy consists of weekly pegylated interferon
injections and daily ribavirin pills, whose dosage is weight based. This regimen in genotype
1 patients is effective in only 45% of patients at best. In addition, this therapy must be
given for 48 weeks to be effective and has alot of side-effects. One risk factor for a poor
response is fatty liver. Rosiglitazone has been shown to be effective in the treatment of
patients with fatty liver alone. This study hopes to show that the addition of Rosiglitazone
to the standard therapy in genotype 1 patients with fatty liver disease will increase
effectiveness of the standard therapy of hepatitis C.